TITLE:
Actual Data on the Efficacy and Safety of Gemcitabine-Docetaxel as Second-Line and Beyond Treatment in Adult Patients with Metastatic Bone Sarcomas: Experience from a Single Institution
AUTHORS:
Medyouni Hajar, Chouef Jihane, Siyouri Oumaima, Chbihi Chaymae, Mhirech Samia, Amaadour Lamiae, Oualla Karima, Benbrahim Zineb, Arifi Samia, Mellas Nawfel
KEYWORDS:
Bone sarcomas, Metastatic, Recurrent, Gemcitabine, Docetaxel
JOURNAL NAME:
Open Access Library Journal,
Vol.11 No.4,
April
12,
2024
ABSTRACT: Osteosarcoma, the most prevalent primary malignant bone tumor in
chil-dren, presents significant challenges in treatment, particularly in cases
of recurrence or refractory disease. This retrospective study explores the
ef-ficacy and safety of gemcitabine-docetaxel (GD) combination therapy as
second-line or later treatment in adult patients with advanced bone sarco-mas.
Twenty-two patients received GD, with 64% showing overall disease control.
Median progression-free survival (PFS) was 5 months, and median overall
survival (OS) was 8.5 months. Adverse events were manageable, with mainly myelosuppression
observed, principally neutropenia followed by anemia and thrombocytopenia,
(grade 1 - 2). Despite limitations such as retrospective design and small
sample size, GD demonstrated tolerability and modest efficacy, offering a
potential treatment option for refractory or recurrent high-grade osteosarcoma
where limited alternatives exist.